Drug intelligence / Profile preview

NANT MCC Vaccine

Development stage: Unknown
Lead developer: ImmunityBio
Modality: Vaccines & Immunotherapeutics

Overview

NANT MCC Vaccine is a combination immunotherapy vaccine developed by ImmunityBio, Inc. for the treatment of Merkel Cell Carcinoma (MCC). It is being evaluated in a Phase 1b/2 clinical study for subjects with MCC who have progressed on or after anti-programmed death-ligand 1 (PD-L1) therapy. The vaccine is designed to stimulate an immune response against Merkel Cell Carcinoma cells as part of a broader metronomic combination therapy regimen.

Other names: NANT Merkel Cell Carcinoma Vaccine

Targets

MCPyV LT/sT (Merkel cell polyomavirus tumor antigens)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on NANT MCC Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NANT MCC Vaccine.

Explore the full profile